Sources: Clarivate Analytics Cortellis database. Tables of approved mAbs and antibodies in review available at: https://www.antibodysociety.org/resources/approved-antibodies/ (1) Defined as composite success rate of clinical development from Phase I trials to Approval, data from 2011-2020. Source: BIO | QLS Advisors | Informa Feb 2021 Report. (1) Represents the unique number of partners that have an active program or have executed a license agreement in advance of initiating an active program. (2) Represent ...

OmniAb, Inc. (NASDAQ:OABI) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Kurt Gustafson - CFO Matt Foehr - President, CEO Conference Call Participants Nishant Gandhi - Truist Securities Stephen Willey - Stifel Joe Pantginis - H.C. Wainwright Puneet Souda - SVB Securities Steven Mah - TD Securities Matt Hewitt - Craig-Hallum Capital Group Operator Good morning, and welcome to the OmniAb Inc.'s First Quarter 2023 Financial Results and Business Update Conference Call. At this ti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________ FORM 10-Q ________________________________________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Pe ...

1 Disclaimer Information regarding partnered products and programs comes from information publicly released by our partners. | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |------------|--------------|-------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Introduction | | | | | | | | | | Matt Foehr | | | | | | | | | | OUR BUSINESS MODEL IS FOCUSED ON LICENSING OUR PROPRIETARY DISCOVERY TECHNO ...

OmniAb, Inc. (NASDAQ:OABI) Q4 2022 Earnings Conference Call March 30, 2023 8:00 AM ET Company Participants Kurt Gustafson - CFO Matt Foehr - President and CEO Conference Call Participants Nishant Gandhi - Truist Securities Joseph Pantginis - H.C. Wainwright & Co. Steven Mah - TD Cowen Puneet Souda - SVB Securities Yuan Zhi - B. Riley FBR Operator Good afternoon, ladies and gentlemen, and welcome to the OmniAb, Inc., Fourth Quarter and Full Year of '22 Earnings Conference Call. At this time all lines are in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________________ FORM 10-K _____________________________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR Registrant's telephone number, including area code: (510) 250-7800 Securities registered pursuant to Section ...

TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Table of Contents As filed with the Securities and Exchange Commission on February 6, 2023 Registration No. 333-268613 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 2 OMNIAB, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 8731 98-1584818 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identif ...

Table of Contents As filed with the Securities and Exchange Commission on January 5, 2023 Registration No. 333-268613 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OMNIAB, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 8731 98-1584818 (I.R.S. Employer Identifi ...

For the quarterly period ended September 30, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-Q (Mark One) Table of Contents ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-40720 OmniAb, Inc. (Exact name of registrant as specified in its charter) | Delaware ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-40720 AVISTA PUBLIC ACQUISITION CORP. II (Exact name of registrant as specified in its cha ...